X

Trial Profile

A clinical trial of Synthetic alpha interferon (Alfacyte) in COVID-19 infections

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 19 May 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Synthetic alpha interferon-ILC Therapeutics (Primary)
Indications COVID 2019 infections
Focus Adverse reactions

Most Recent Events

13 May 2021 According to an ILC Therapeutics media release, company is preparing Alfacyte to complete the IND application. The company has engaged 3P Bio SA, a leading biologics production service company based in Spain, for the manufacture of Alfacyte as well as UK-based contract research organisation TCRS for clinical trials which are being planned for early 2022.
10 Dec 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com